Bank of New York Mellon Corp - CATALYST PHARMACEUTICALS INC ownership

CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 138 filers reported holding CATALYST PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.04 and the average weighting 0.1%.

Quarter-by-quarter ownership
Bank of New York Mellon Corp ownership history of CATALYST PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$9,237,041
-14.2%
790,166
-1.3%
0.00%0.0%
Q2 2023$10,763,101
-20.7%
800,826
-2.2%
0.00%
-33.3%
Q1 2023$13,578,987
-15.5%
818,998
-5.2%
0.00%
-25.0%
Q4 2022$16,061,565
+36.6%
863,525
-5.8%
0.00%
+33.3%
Q3 2022$11,759,000
+235.0%
916,396
+83.0%
0.00%
+200.0%
Q2 2022$3,510,000
-25.7%
500,766
-12.1%
0.00%0.0%
Q1 2022$4,722,000
+42.9%
569,542
+16.7%
0.00%0.0%
Q4 2021$3,305,000
-4.9%
488,217
-25.5%
0.00%0.0%
Q3 2021$3,475,000
-2.7%
655,517
+5.5%
0.00%0.0%
Q2 2021$3,573,000
+21.9%
621,474
-2.3%
0.00%0.0%
Q1 2021$2,932,000
+40.2%
635,909
+1.6%
0.00%
Q4 2020$2,091,000
+63.6%
626,022
+45.5%
0.00%
Q3 2020$1,278,000
-34.1%
430,333
+2.5%
0.00%
-100.0%
Q2 2020$1,939,000
+17.7%
419,806
-1.9%
0.00%0.0%
Q1 2020$1,647,000
+1.4%
427,802
-1.2%
0.00%
Q4 2019$1,624,000
-21.1%
433,126
+11.7%
0.00%
-100.0%
Q3 2019$2,058,000
+51.9%
387,694
+9.9%
0.00%
Q2 2019$1,355,000
-42.2%
352,902
-23.2%
0.00%
-100.0%
Q1 2019$2,344,000
+265.7%
459,751
+37.6%
0.00%
Q4 2018$641,000
-45.0%
334,078
+8.3%
0.00%
Q3 2018$1,166,000
+35.9%
308,580
+12.3%
0.00%
Q2 2018$858,000
+51.1%
274,813
+15.7%
0.00%
Q1 2018$568,000
-68.0%
237,425
-47.7%
0.00%
Q4 2017$1,777,000
+229.7%
454,374
+112.5%
0.00%
Q3 2017$539,000
-7.9%
213,837
+0.9%
0.00%
Q2 2017$585,000
+333.3%
211,979
+206.4%
0.00%
Q1 2017$135,000
+92.9%
69,176
+3.6%
0.00%
Q4 2016$70,000
-9.1%
66,772
-6.0%
0.00%
Q3 2016$77,000
+30.5%
71,038
-14.7%
0.00%
Q2 2016$59,000
-79.3%
83,266
-65.8%
0.00%
Q1 2016$285,000
-56.4%
243,198
-8.9%
0.00%
Q4 2015$654,000
-18.6%
266,820
-0.2%
0.00%
Q3 2015$803,000
-37.4%
267,475
-13.8%
0.00%
Q2 2015$1,282,000
+221.3%
310,422
+236.7%
0.00%
Q1 2015$399,000
+45.6%
92,201
-0.0%
0.00%
Q4 2014$274,000
+23.4%
92,241
+37.8%
0.00%
Q3 2014$222,000
-64.5%
66,956
-73.0%
0.00%
Q2 2014$626,000
+124.4%
247,790
+101.1%
0.00%
Q1 2014$279,000
+40.9%
123,237
+21.6%
0.00%
Q4 2013$198,000
-68.0%
101,363
-50.0%
0.00%
Q3 2013$618,000202,7260.00%
Other shareholders
CATALYST PHARMACEUTICALS INC shareholders Q4 2020
NameSharesValueWeighting ↓
TANAKA CAPITAL MANAGEMENT INC 148,281$2,4587.14%
GABLES CAPITAL MANAGEMENT INC. 409,080$6,782,5464.74%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 10,355,099$171,687,5413.83%
JW Asset Management, LLC 563,392$9,341,0393.58%
Quantedge Capital Pte Ltd 324,700$5,383,5262.10%
Paradiem, LLC 236,628$3,923,2921.22%
SummerHaven Investment Management, LLC 100,592$1,667,8150.97%
Capital Impact Advisors, LLC 46,096$764,2720.94%
Yorktown Management & Research Co Inc 50,000$829,0000.89%
Seaport Global Advisors, LLC 15,598$258,6150.82%
View complete list of CATALYST PHARMACEUTICALS INC shareholders